511 related articles for article (PubMed ID: 31040672)
1. Natamycin solid lipid nanoparticles - sustained ocular delivery system of higher corneal penetration against deep fungal keratitis: preparation and optimization.
Khames A; Khaleel MA; El-Badawy MF; El-Nezhawy AOH
Int J Nanomedicine; 2019; 14():2515-2531. PubMed ID: 31040672
[TBL] [Abstract][Full Text] [Related]
2. Natamycin niosomes as a promising ocular nanosized delivery system with ketorolac tromethamine for dual effects for treatment of candida rabbit keratitis; in vitro/in vivo and histopathological studies.
El-Nabarawi MA; Abd El Rehem RT; Teaima M; Abary M; El-Mofty HM; Khafagy MM; Lotfy NM; Salah M
Drug Dev Ind Pharm; 2019 Jun; 45(6):922-936. PubMed ID: 30744431
[TBL] [Abstract][Full Text] [Related]
3. The preparation and therapeutic effects of β-glucan-specific nanobodies and nanobody-natamycin conjugates in fungal keratitis.
Liu X; Sui J; Li C; Wang Q; Peng X; Meng F; Xu Q; Jiang N; Zhao G; Lin J
Acta Biomater; 2023 Oct; 169():398-409. PubMed ID: 37579912
[TBL] [Abstract][Full Text] [Related]
4. Corneal targeted nanoparticles for sustained natamycin delivery and their PK/PD indices: an approach to reduce dose and dosing frequency.
Chandasana H; Prasad YD; Chhonker YS; Chaitanya TK; Mishra NN; Mitra K; Shukla PK; Bhatta RS
Int J Pharm; 2014 Dec; 477(1-2):317-25. PubMed ID: 25455776
[TBL] [Abstract][Full Text] [Related]
5. Thermosensitive Tri-Block Polymer Nanoparticle-Hydrogel Composites as Payloads of Natamycin for Antifungal Therapy Against
Sha X; Chan L; Fan X; Guo P; Chen T; Liu L; Zhong J
Int J Nanomedicine; 2022; 17():1463-1478. PubMed ID: 35378880
[TBL] [Abstract][Full Text] [Related]
6. Implementing polymeric pseudorotaxanes for boosting corneal permeability and antiaspergillus activity of tolnaftate: formulation development, statistical optimization, ex vivo permeation and in vivo assessment.
Aziz D; Mohamed S; Tayel S; Makhlouf A
Drug Deliv; 2022 Dec; 29(1):2162-2176. PubMed ID: 35815689
[TBL] [Abstract][Full Text] [Related]
7. Ocular amphotericin B delivery by chitosan-modified nanostructured lipid carriers for fungal keratitis-targeted therapy.
Fu T; Yi J; Lv S; Zhang B
J Liposome Res; 2017 Sep; 27(3):228-233. PubMed ID: 27601177
[TBL] [Abstract][Full Text] [Related]
8. Cell penetrating peptides as efficient nanocarriers for delivery of antifungal compound, natamycin for the treatment of fungal keratitis.
Jain A; Shah SG; Chugh A
Pharm Res; 2015 Jun; 32(6):1920-30. PubMed ID: 25467959
[TBL] [Abstract][Full Text] [Related]
9. Nanocubosomal based
Hosny KM; Rizg WY; Alkhalidi HM; Abualsunun WA; Bakhaidar RB; Almehmady AM; Alghaith AF; Alshehri S; El Sisi AM
Drug Deliv; 2021 Dec; 28(1):1836-1848. PubMed ID: 34515597
[TBL] [Abstract][Full Text] [Related]
10. Reduced administration frequency for the treatment of fungal keratitis: a sustained natamycin release from a micellar solution.
Guo Y; Karimi F; Fu Q; G Qiao G; Zhang H
Expert Opin Drug Deliv; 2020 Mar; 17(3):407-421. PubMed ID: 32009483
[No Abstract] [Full Text] [Related]
11. Formulation design and optimization of cationic-charged liposomes of brimonidine tartrate for effective ocular drug delivery by design of experiment (DoE) approach.
Soni PK; Saini TR
Drug Dev Ind Pharm; 2021 Nov; 47(11):1847-1866. PubMed ID: 35484943
[TBL] [Abstract][Full Text] [Related]
12. Optimization of β-cyclodextrin consolidated micellar dispersion for promoting the transcorneal permeation of a practically insoluble drug.
Sayed S; Elsayed I; Ismail MM
Int J Pharm; 2018 Oct; 549(1-2):249-260. PubMed ID: 30077759
[TBL] [Abstract][Full Text] [Related]
13. Systematic optimization of cationic surface engineered mucoadhesive vesicles employing Design of Experiment (DoE): A preclinical investigation.
Verma A; Sharma G; Jain A; Tiwari A; Saraf S; Panda PK; Katare OP; Jain SK
Int J Biol Macromol; 2019 Jul; 133():1142-1155. PubMed ID: 31004631
[TBL] [Abstract][Full Text] [Related]
14. Laccase-mediated functionalization of natamycin by gallic acids for the therapeutic effect on Aspergillus fumigatus keratitis.
Ji X; Peng X; Long X; Zhang Y; Lin J; Yin J; Zhang R; Zhao G
Eur J Pharmacol; 2022 Jul; 926():175041. PubMed ID: 35597265
[TBL] [Abstract][Full Text] [Related]
15. Natamycin Ocular Delivery: Challenges and Advancements in Ocular Therapeutics.
Mascarenhas M; Chaudhari P; Lewis SA
Adv Ther; 2023 Aug; 40(8):3332-3359. PubMed ID: 37289410
[TBL] [Abstract][Full Text] [Related]
16. Fabrication of a drug delivery system that enhances antifungal drug corneal penetration.
Li J; Li Z; Liang Z; Han L; Feng H; He S; Zhang J
Drug Deliv; 2018 Nov; 25(1):938-949. PubMed ID: 29658325
[TBL] [Abstract][Full Text] [Related]
17. Application of Box-Behnken design for preparation of levofloxacin-loaded stearic acid solid lipid nanoparticles for ocular delivery: Optimization, in vitro release, ocular tolerance, and antibacterial activity.
Baig MS; Ahad A; Aslam M; Imam SS; Aqil M; Ali A
Int J Biol Macromol; 2016 Apr; 85():258-70. PubMed ID: 26740466
[TBL] [Abstract][Full Text] [Related]
18. Novel nanomicelle butenafine formulation for ocular drug delivery against fungal keratitis: In Vitro and In Vivo study.
Lu P; Liang Z; Zhang Z; Yang J; Song F; Zhou T; Li J; Zhang J
Eur J Pharm Sci; 2024 Jan; 192():106629. PubMed ID: 37918544
[TBL] [Abstract][Full Text] [Related]
19. Niosomes: Do They Increase the Potency of Topical Natamycin Ketorolac Formula in Treating Aspergillus Keratitis? An Experimental Study.
El-Mofty HM; El-Nabarawi MA; Abd El Rehem RT; Teaima MH; Abary MYS; Salah M; Lotfy NM
J Ocul Pharmacol Ther; 2020 Sep; 36(7):545-554. PubMed ID: 32357092
[No Abstract] [Full Text] [Related]
20. Assessment to the Antifungal Effects in vitro and the Ocular Pharmacokinetics of Solid-Lipid Nanoparticle in Rabbits.
Liang Z; Zhang Z; Yang J; Lu P; Zhou T; Li J; Zhang J
Int J Nanomedicine; 2021; 16():7847-7857. PubMed ID: 34876813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
